Literature DB >> 7737234

A comparative study of uranyl nitrate and cisplatin-induced renal failure in rat.

I Mahmood1, D H Waters.   

Abstract

Renal dysfunction can have substantial effects on the pharmacokinetics and pharmacodynamics of drugs. A wide variety of animal models have been developed in an attempt to mimic conditions seen in human renal failure. In reality, no single animal model would be completely satisfactory because the etiology and development of renal failure are diverse. During recent years injection of uranyl nitrate has been found to be the most effective and easiest method to produce renal dysfunction in laboratory animals. Changes over the last 10 years in government regulations on the production and use of radioactive substances make the compound less available. There is, therefore, a need for a more accessible compound comparable to uranyl nitrate as an inducer of renal failure. The present study compares the effects of another known nephrotoxin, cisplatin, with uranyl nitrate in the rat. Cisplatin was chosen because of its ability to produce kidney damage and its identical site and mechanism of action on the kidneys as uranyl nitrate. In the present study, rats were given different i.v. doses of uranyl nitrate or cisplatin dissolved in 0.9% of saline solution. The effects of nephrotoxins were evaluated on the basis of changes in body weight, creatinine and blood urea nitrogen (BUN) concentrations. It was found that the degree of renal damage produced by uranyl nitrate and cisplatin is a function of the administered dose. With increasing dose there is evidence of more severe kidney damage, as measured by substantially increased plasma concentrations of creatinine and BUN. The time required to return to normal creatinine and BUN concentrations was also a function of dose. Furthermore, plasma alanine aminotransferase (ALT) activity was measured as an index of hepatocellular damage. The ALT test showed that a single dose does not affect the liver function. From dose-response curves a dose of 4 mg/kg body weight of uranyl nitrate or cisplatin was chosen to produce acute renal failure in animals for pharmacokinetic study of barbital. Barbital (100 mg/kg) was administered on the fifth day (the day of maximum renal dysfunction) to uranyl nitrate, cisplatin-treated and control rats. The elimination rate constant (k), elimination half life (t1/2), volume of distribution at steady state (Vss), total (CLt) and renal clearance (CLr) were significantly different in treated groups of rats from control, however no such difference was detected between uranyl nitrate and cisplatin-treated group of rats. In short, cisplatin is comparable to uranyl nitrate in producing renal failure in the rat and can be considered a suitable alternative.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7737234     DOI: 10.1007/BF03188859

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  21 in total

1.  The general pharmacology of the heavy metals.

Authors:  H PASSOW; A ROTHSTEIN; T W CLARKSON
Journal:  Pharmacol Rev       Date:  1961-06       Impact factor: 25.468

2.  The interaction of barbiturates with serum albumin and its possible relation to their disposition and pharmacological actions.

Authors:  L R GOLDBAUM; P K SMITH
Journal:  J Pharmacol Exp Ther       Date:  1954-06       Impact factor: 4.030

3.  The metabolism of barbiturates.

Authors:  E W MAYNERT; H B VAN DYKE
Journal:  Pharmacol Rev       Date:  1949       Impact factor: 25.468

4.  Computer program for the parametric and nonparametric comparison of several groups to a control.

Authors:  W D Blaker
Journal:  Comput Biol Med       Date:  1987       Impact factor: 4.589

5.  Repair of the nephron following injury with mercuric chloride.

Authors:  F E Cuppage; A Tate
Journal:  Am J Pathol       Date:  1967-09       Impact factor: 4.307

6.  Clinical trials of cis-diamminedichloroplatinum (NSC-119875).

Authors:  A J Lippman; C Helson; L Helson; I H Krakoff
Journal:  Cancer Chemother Rep       Date:  1973-04

7.  Acute toxicologic and pathologic effects of cis-diamminedichloroplatinum (NSC-119875) in the male rat.

Authors:  R J Kociba; S D Sleight
Journal:  Cancer Chemother Rep       Date:  1971-02

8.  Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

Review 9.  Renal failure, drug pharmacokinetics and drug action.

Authors:  J Fabre; L Balant
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

10.  Distal Tubule [Na+] and juxtaglomerular apparatus Renin activity in uranyl nitrate induced acute renal failure in the rat. An evaluation of the role of tubuloglomerular feedback.

Authors:  W Flamenbaum; R Hamburger; J Kaufman
Journal:  Pflugers Arch       Date:  1976-08-24       Impact factor: 3.657

View more
  4 in total

1.  In vitro and in vivo activities of amikacin, cefepime, amikacin plus cefepime, and imipenem against an SHV-5 extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain.

Authors:  D Szabó; A Máthé; Z Filetóth; P Anderlik; L Rókusz; F Rozgonyi
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

2.  Amoxicillin is effective against penicillin-resistant Streptococcus pneumoniae strains in a mouse pneumonia model simulating human pharmacokinetics.

Authors:  Pierre Abgueguen; Esther Azoulay-Dupuis; Violaine Noel; Pierre Moine; Veronique Rieux; Bruno Fantin; Jean-Pierre Bedos
Journal:  Antimicrob Agents Chemother       Date:  2006-10-23       Impact factor: 5.191

3.  Blood chemical changes and renal histological alterations induced by gentamicin in rats.

Authors:  Saud Alarifi; Amin Al-Doaiss; Saad Alkahtani; S A Al-Farraj; Mohammed Saad Al-Eissa; B Al-Dahmash; Hamad Al-Yahya; Mohammed Mubarak
Journal:  Saudi J Biol Sci       Date:  2011-12-03       Impact factor: 4.219

4.  The hepatic and intestinal metabolic activities of P450 in rats with surgery- and drug-induced renal dysfunction.

Authors:  Hiromi Okabe; Miyako Hasunuma; Yukiya Hashimoto
Journal:  Pharm Res       Date:  2003-10       Impact factor: 4.200

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.